PMID- 17005045
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20070808
LR  - 20200930
IS  - 1477-9560 (Electronic)
IS  - 1477-9560 (Linking)
VI  - 4
DP  - 2006 Sep 27
TI  - Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in 
      medical inpatients.
PG  - 17
AB  - BACKGROUND: Clinical trials have shown low-molecular weight heparin (LMWH) to be 
      at least as safe and efficacious as unfractionated heparin (UFH) for preventing 
      venous thromboembolism (VTE) in acutely-ill medical inpatients. OBJECTIVE: To 
      compare clinical and economic outcomes among acutely-ill medical inpatients 
      receiving the LMWH enoxaparin versus UFH prophylaxis in clinical practice. 
      METHODS: Using a large, multi-hospital, US database, we identified persons aged > 
      or =40 years hospitalized for > or =6 days for an acute medical condition 
      (including circulatory disorders, respiratory disorders, infectious diseases, or 
      neoplasms) from Q4 1999 to Q1 2002. From these patients, those who received 
      thromboprophylaxis with either enoxaparin or UFH were identified. Surgical 
      patients and those requiring or ineligible for anticoagulation were excluded. We 
      compared the incidence of deep-vein thrombosis (DVT), pulmonary embolism (PE), 
      and all VTE (i.e., DVT and/or PE). Secondary outcomes were occurrence of 
      side-effects, length of hospital stay and total costs. RESULTS: 479 patients 
      received enoxaparin prophylaxis and 2,837 received UFH. The incidence of VTE was 
      1.7% with enoxaparin prophylaxis versus 6.3% with UFH (RR = 0.26; p < 0.001). 
      Occurrence of side effects, length of stay (10.00 days with enoxaparin vs. 10.26 
      days with UFH; p = 0.348) and total costs ($18,777 vs. $17,602; p = 0.463) were 
      similar in the 2 groups. CONCLUSION: We observed a 74% lower risk of VTE among 
      patients receiving enoxaparin prophylaxis versus UFH prophylaxis. There was no 
      significant difference in side effects or economic outcomes. These results 
      provide evidence that the LMWH enoxaparin is more effective than UFH in reducing 
      the risk of VTE in current clinical practice.
FAU - McGarry, Lisa J
AU  - McGarry LJ
AD  - Health Economics & Outcomes Research, i3 Innovus, 10 Cabot Rd, Suite 304, 
      Medford, MA 02155-5173, USA.
FAU - Stokes, Michael E
AU  - Stokes ME
FAU - Thompson, David
AU  - Thompson D
LA  - eng
PT  - Journal Article
DEP - 20060927
PL  - England
TA  - Thromb J
JT  - Thrombosis journal
JID - 101170542
PMC - PMC1624807
EDAT- 2006/09/29 09:00
MHDA- 2006/09/29 09:01
PMCR- 2006/09/27
CRDT- 2006/09/29 09:00
PHST- 2005/12/08 00:00 [received]
PHST- 2006/09/27 00:00 [accepted]
PHST- 2006/09/29 09:00 [pubmed]
PHST- 2006/09/29 09:01 [medline]
PHST- 2006/09/29 09:00 [entrez]
PHST- 2006/09/27 00:00 [pmc-release]
AID - 1477-9560-4-17 [pii]
AID - 10.1186/1477-9560-4-17 [doi]
PST - epublish
SO  - Thromb J. 2006 Sep 27;4:17. doi: 10.1186/1477-9560-4-17.